Semaglutide is a glucagon-like peptide 1 (GLP-1) medication whose shortage has been in effect since 2022
Rodbard HW, Bode BW, Harris SB, et al
Extended Dosing Horizons : By proving that cAMP levels can be pharmacologically sustained, this integrated protocol suggests that future GLP-1 treatments could be modified to last significantly longer, potentially reducing how frequently a patient must take the medication
We also conducted an as treated analysis assessing only active treatment from first initiation until first break of treatment, where cohort members were followed from index date until first registration of suicide or suicide attempts, emigration, death, switching to the other study drug or reaching the end of their first treatment period
Many patients find that the appetite-suppressing effects of semaglutide make it easier to adopt healthier eating patterns that naturally support lipid improvement
The 5-HT2C receptor is the same one implicated in the sexual side effects of SSRI antidepressants